about
Pharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method.Molecular dynamics simulation of dimeric and monomeric forms of human prion protein: insight into dynamics and propertiesIdentification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target.Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.Accelerating quantum chemistry calculations with graphical processing units - toward in high-density (HD) silico drug discovery.In silico, in vitro, X-ray crystallography, and integrated strategies for discovering spermidine synthase inhibitors for Chagas disease.Exploring the selectivity of inhibitor complexes with Bcl-2 and Bcl-XL: A molecular dynamics simulation approach.Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease.Database of the clinical phenotypes, genotypes and mutant arylsulfatase B structures in mucopolysaccharidosis type VIMembrane Phospholipid Analogues as Molecular Rulers to Probe the Position of the Hydrophobic Contact Point of Lysophospholipid Ligands on the Surface of G-Protein-Coupled Receptor during Membrane ApproachProAffiMuSeq: sequence-based method to predict the binding free energy change of protein-protein complexes upon mutation using functional classificationMolecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxilImproved Method of Structure-Based Virtual Screening via Interaction-Energy-Based LearningA prospective compound screening contest identified broader inhibitors for Sirtuin 1
P50
Q28547166-1CB05248-E364-46F2-8642-41E71F8A208DQ34182352-B515F2B5-6527-480B-84FE-BB928371AF0EQ36320975-8AB94D6A-D156-4789-8AAE-885A1D85A6C7Q36606607-249C0C8E-E168-4B66-84DA-46D01BD9691AQ38134832-9B662972-6163-4594-9A29-09E6CC8AE270Q39617576-A02E7922-3CEB-4A54-ABF2-F48D7AAE1BB3Q47338461-0896B0DC-89F3-4A18-9D5C-AC087C5A1F8AQ51737715-569F0009-932E-4EA9-AF11-79534BBD4E98Q83453417-09402065-81A6-4B10-B488-D398B5A4CC14Q89988352-49932354-72F4-4D81-9EF1-CAF866DCB3B9Q91239944-421DC7C9-BAB7-4E72-9DE8-9A2F98F47017Q91452095-18062124-7955-4600-BB82-E884F3307360Q91938515-8A63B428-C41D-4DBB-B1A2-7F4CF6C92AD4Q92163956-268075D0-2FC3-4C23-B8EA-D09970E9742F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Masakazu Sekijima
@ast
Masakazu Sekijima
@en
Masakazu Sekijima
@es
Masakazu Sekijima
@nl
type
label
Masakazu Sekijima
@ast
Masakazu Sekijima
@en
Masakazu Sekijima
@es
Masakazu Sekijima
@nl
prefLabel
Masakazu Sekijima
@ast
Masakazu Sekijima
@en
Masakazu Sekijima
@es
Masakazu Sekijima
@nl
P106
P31
P496
0000-0002-3806-9535